The use of recombinant BoNT domains has been proposed as a means to develop strategies to treat and prevent botulism. Here, details on the molecular cloning, protein expression, purification, and immunoreactivity of BoNT/F domains from Clostridium botulinum are presented. Initially, fulllength synthetic genes encoding recombinant BoNT/F domains (catalytic, translocation, and receptor binding) were designed and cloned into Escherichia coli for expression. Recombinant proteins were then purified through GST affinity chromatography preceding elution of GST-free recombinant domains by thrombin protease. Soluble recombinant proteins encoding catalytic light chain and translocation N-terminal heavy chain were subsequently used to perform in vivo immunization. Polyclonal mouse antibodies specific to these domains were raised, confirmed by Western blot analysis and elevated immunoreactivity was identified through indirect ELISA. In conclusion, availability of the recombinant protein provides an effective system to study the immunological aspects of BoNT/F and corresponding applications in pathogen detection and vaccine candidacy.
applications in cosmetics [8] and therapeutics for the treatment of numerous dystonias, inflammation, and chronic pain [9] [10] [11] .
Botulinum neurotoxin serotype F (BoNT/F), is a member of the botulinum neurotoxin family as a single ~150 kDa inactive polypeptide chain post-translationally nicked, forming a dichain consisting of a C-terminal ~100 kDa heavy chain (HC) and a N-terminal ~50 kDa light chain (LC) linked by a disulphide bond [12, 13] . BoNT/F cleaves its substrate vesicle associated membrane protein (VAMP) at position (Gln 58 -Lys 59 ) [14, 15] , one of three neuronal proteins associated with exocytosis; subsequently inhibiting acetylcholine release, resulting in death by flaccid paralysis [16, 17] . [20] . Botulinum neurotoxin HNs possesses channel-forming capability in the acidic environment of the endosome, allowing internalization of the toxin, while HCs are involved in specific binding to the presynaptic membrane via gangliosides and a protein co-receptor [21] . Lastly, the HCc region of BoNTs are known to harbor the receptor binding neutralizing epitopes which are targets for antibodies that can specifically bind to the receptor, and show neutralizing activity against BoNT toxicity [22] .
Thus, it is imperative to construct each domain for the analysis of their molecular and biochemical activities as well as for the development of potential neutralizing antibodies specific to each. To achieve this goal, BoNT/F domains from C. botulinum were cloned and expressed using a high expression vector and compatible host E. coli strains to obtain high quality of recombinant proteins suitable for administration into mice.
Methods

Chemicals, Buffers, and Reagents
Components related to DNA manipulation, including Ex-Taq polymerase, dNTP, and restriction enzymes were purchased from Takara Bio. Inc., (Shiga, Japan 
Results and Discussion
The Subsequently the recombinant plasmids were digested with restriction enzymes (Table 1) and appropriate band sizes were identified for both pGEX-4T-1 (4.9 kb) and all individual fragment sizes ( Fig. 3 ). 
